Evelo: Evelo (EVLO) Drops 59% on Flunking Psoriasis Drug Study
Evelo's (EVLO) EDP2939 fails to achieve the primary endpoint in a mid-stage for treating moderate psoriasis. The company decides to cease clinical development on the candidate.
Read full article »
President & CEO
Balkrishan Gill
Evelo is a Massachusetts-based biotechnology company that researches and develops oral medicines for the treatment of patients with inflammatory diseases.
Read more